In conjunction, the inhibition of PI3K-AKT-ERK signaling by a PI3K-AKT dual kinase inhibitor abrogated the oncogenic characteristics such as cancer stemness, chemoresistance and EMT. This evidence concerns the gene AKT1 and cancer.